Aileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest Update

Aileron Therapeutics, Inc. (NASDAQ:ALRN) saw a large decrease in short interest in October. As of October 31st, there was short interest totalling 233,300 shares, a decrease of 8.7% from the October 15th total of 255,600 shares. Based on an average daily volume of 74,800 shares, the short-interest ratio is presently 3.1 days. Currently, 1.2% of the company’s stock are short sold.

Aileron Therapeutics Trading Down 13.3 %

NASDAQ ALRN opened at $2.87 on Monday. Aileron Therapeutics has a 12 month low of $1.57 and a 12 month high of $7.42. The stock has a 50 day moving average of $3.48 and a 200-day moving average of $3.13. The company has a market cap of $62.18 million, a PE ratio of -0.92 and a beta of 2.35.

Institutional Trading of Aileron Therapeutics

A number of large investors have recently added to or reduced their stakes in ALRN. University of Texas Texas AM Investment Management Co. bought a new stake in shares of Aileron Therapeutics in the 2nd quarter valued at about $4,925,000. Nantahala Capital Management LLC raised its stake in Aileron Therapeutics by 82.1% in the second quarter. Nantahala Capital Management LLC now owns 464,367 shares of the company’s stock valued at $1,286,000 after buying an additional 209,367 shares during the period. Geode Capital Management LLC lifted its position in shares of Aileron Therapeutics by 34.8% in the third quarter. Geode Capital Management LLC now owns 229,817 shares of the company’s stock valued at $814,000 after buying an additional 59,370 shares during the last quarter. Sigma Planning Corp lifted its position in shares of Aileron Therapeutics by 68.3% in the third quarter. Sigma Planning Corp now owns 212,410 shares of the company’s stock valued at $752,000 after buying an additional 86,185 shares during the last quarter. Finally, Warberg Asset Management LLC bought a new position in shares of Aileron Therapeutics during the 2nd quarter worth approximately $86,000. Institutional investors and hedge funds own 90.89% of the company’s stock.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc, a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).